← Back to Search

Tyrosine Kinase Inhibitor

Active for Non-Small Cell Lung Cancer (RAIN Trial)

Phase 2
Waitlist Available
Led By Stephen V Liu, MD
Research Sponsored by Rain Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 10 months.
Awards & highlights
No Placebo-Only Group

Summary

Open-label, Phase 2, single treatment arm, 3 cohorts

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Epidermal Growth Factor Receptor Mutations
  • Breast Cancer
  • ERBB Fusion
  • Neuroblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 10 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 10 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ORR

Side effects data

From 2015 Phase 4 trial • 88 Patients • NCT02125734
5%
Cough
2%
Nasal congestion
2%
Headache
2%
Nasopharyngitis
1%
Pain in extremity
1%
Palpitations
1%
Productive cough
1%
Fluid retention
1%
Muscle spasms
1%
Hypertension
1%
Dyspnoea
1%
Pruritus
1%
Renal pain
1%
Hypertriglyceridaemia
1%
Arthralgia
1%
Rhinorrhoea
1%
Nausea
1%
Peripheral swelling
1%
Bronchitis
1%
Herpes zoster
1%
Rhinitis
1%
Sinusitis
1%
Laceration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tiotropium
QVA149

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ActiveExperimental Treatment1 Intervention
tarloxotinib bromide

Find a Location

Who is running the clinical trial?

Rain Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
241 Total Patients Enrolled
Rain Oncology IncLead Sponsor
8 Previous Clinical Trials
278 Total Patients Enrolled
Stephen V Liu, MDPrincipal InvestigatorGeorgetown University
~6 spots leftby Oct 2025